Welcome to our dedicated page for Nurix Therapeutics news (Ticker: NRIX), a resource for investors and traders seeking the latest updates and insights on Nurix Therapeutics stock.
Nurix Therapeutics, Inc. (Nasdaq: NRIX) is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapies that modulate cellular protein levels. Leveraging their proprietary drug discovery platform, DELigase, Nurix focuses on a novel approach to target E3 ubiquitin ligases within the ubiquitin-proteasome system (UPS). This system regulates protein stabilization and degradation, providing therapeutic opportunities across various disease areas.
Founded by experts in the UPS field and initially funded by leading investors such as Third Rock Ventures and The Column Group, Nurix has positioned itself as a leader in developing first-in-class therapies. The company’s pipeline includes drug candidates that target protein degraders of Bruton's tyrosine kinase (BTK) and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B). Their lead product candidate, NX-2127, is an orally available BTK degrader designed to treat relapsed or refractory B-cell malignancies. Another key candidate, NX-1607, is an orally available CBL-B inhibitor aimed at immuno-oncology indications.
Partnering with industry giants like Celgene, Sanofi, Gilead, and Pfizer, Nurix continues to expand its reach and capabilities. One significant collaboration with Sanofi targets the STAT6 pathway, a critical player in type 2 inflammation. The extension of this collaboration underscores the success and productivity of their ongoing research efforts. Nurix’s innovative approach is also evident in their BTK degrader NX-5948, demonstrating promising clinical activity in patients with CNS involvement.
In its recent financial update, Nurix reported strong results for the first quarter of 2024, with increased revenue driven by collaborations and research milestones. Despite reporting a net loss, the company holds substantial cash reserves to support ongoing and future projects. Leadership transitions within Nurix, such as the appointment of Julia P. Gregory as the new board chair, reflect the company’s commitment to strategic growth and innovation.
Headquartered in San Francisco, California, Nurix remains at the forefront of drug discovery and development, aiming to bring transformative therapies to patients with cancer, inflammatory conditions, and other challenging diseases. For more information, visit http://www.nurixtx.com.
Nurix Therapeutics has announced key findings from its presentations at the AACR Annual Meeting, focusing on its lead BTK degrader, NX-2127, and the investigational compound NX-5948. Both compounds exhibit significant efficacy against BTK inhibitor resistance mutations in B-cell malignancies. The results reveal that NX-5948 promotes selective degradation of multiple BTK resistance mutations, outperforming other reported BTK degraders.
NX-2127's structure was first disclosed during this event, alongside preclinical data and initial pharmacokinetic information. These advancements strengthen the rationale for the ongoing clinical trials evaluating these compounds in patients with advanced B-cell malignancies, potentially offering new treatment avenues for patients unresponsive to existing therapies.
Nurix Therapeutics (Nasdaq: NRIX) announced a productive start to 2023, highlighted by Gilead's licensing of NX-0479/GS-6791, a targeted protein degrader of IRAK4, generating a $20 million upfront payment. The collaboration aims to explore applications in rheumatoid arthritis and other inflammatory diseases, offering potential additional milestone payments of up to $425 million. First-quarter collaboration revenue increased to $12.7 million, up from $9.6 million year-over-year, supported by $7.5 million in research milestones from Gilead and Sanofi. However, the company's net loss for the quarter was $40.7 million, or $0.75 per share, down from a loss of $42.5 million or $0.95 per share a year prior. Cash and marketable securities stand at $325.6 million as of February 28, 2023.
Nurix Therapeutics, a clinical-stage biopharmaceutical company focused on targeted protein modulation for treating cancer, announced that President and CEO Arthur T. Sands, M.D., Ph.D., will participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on April 20, 2023, at 3:00 p.m. ET. The event will be available for live streaming, and an archived version will be accessible on the company's website for 30 days post-event.
Nurix's innovative approach includes the discovery and development of small molecules and cell therapies that modulate cellular protein levels using E3 ligases. Their proprietary DELigase platform enables the identification of novel drug candidates targeting E3 ligases, aimed at treating hematologic malignancies and solid tumors. For more information, visit Nurix's website.
Nurix Therapeutics and Gilead Sciences have announced that Gilead has exercised an option to exclusively license Nurix's investigational protein degrader molecule, NX-0479, now designated GS-6791. This trigger represents a major milestone in their 2019 collaboration, providing Nurix with a $20 million option fee, with additional potential payments of up to $425 million dependent on various milestones. GS-6791, a selective IRAK4 degrader, targets inflammatory responses in conditions like rheumatoid arthritis. This development highlights the strategic significance of their collaboration and Nurix's innovative DELigase platform for advancing therapeutic candidates.
Nuri Therapeutics (Nasdaq: NRIX) announced the upcoming presentation of preclinical data on its targeted BTK degraders, NX-2127 and NX-5948, at the AACR 2023 Annual Meeting in Orlando, FL, from April 14-19, 2023. Both compounds are undergoing Phase 1 trials for patients with relapsed or refractory B cell malignancies. Key presentations include NX-2127 as a first-in-class degrader of BTK and IKZF1/3 as well as NX-5948, which selectively degrades inhibitor-resistant BTK mutants. Details will be available for on-demand viewing starting April 14, 2023. Nurix focuses on innovative therapies aimed at modulating protein levels for cancer treatment.
Nurix Therapeutics (Nasdaq: NRIX) will present a corporate overview at the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023, at 10:40 a.m. ET. The presentation by Arthur T. Sands, M.D., Ph.D., the company's president and CEO, will be available via webcast on the Nurix website in the Investors section. The archived webcast will be accessible for 30 days post-event. Nurix, a clinical-stage biopharmaceutical company, focuses on developing targeted protein modulation drugs for cancer treatment. Its proprietary platform, DELigase, aids in discovering novel drug candidates targeting E3 ligases.
FAQ
What is the current stock price of Nurix Therapeutics (NRIX)?
What is the market cap of Nurix Therapeutics (NRIX)?
What does Nurix Therapeutics, Inc. specialize in?
What is the significance of Nurix's DELigase platform?
Who are Nurix's major partners?
What are some of Nurix's key drug candidates?
How has Nurix performed financially in recent quarters?
Where is Nurix Therapeutics headquartered?
What recent leadership changes have occurred at Nurix?
What is the focus of Nurix's collaboration with Sanofi?
What are Nurix's plans for NX-5948?
How can I learn more about Nurix Therapeutics?
